



**Final Appraisal Recommendation**

Advice No: 1713 – July 2013

**Lapatinib (Tyverb<sup>®</sup>) 250 mg film-coated tablets**

**Submission by Novartis Pharmaceuticals UK Ltd**

**Recommendation of AWMSG**

Lapatinib (Tyverb<sup>®</sup>) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2), in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.

Lapatinib (Tyverb<sup>®</sup>) should be restricted within its licensed indication for the treatment of patients as an alternative to treatment with trastuzumab and capecitabine or trastuzumab and vinorelbine in patients in whom clinicians consider this clinically appropriate.

Lapatinib (Tyverb<sup>®</sup>) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

**Additional note(s):**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 178), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

|  |                 |
|--|-----------------|
| Marketing authorisation holder on first issue: | GlaxoSmithKline |
| Date of first issue                            | July 2013       |
| Last reviewed                                  | September 2016  |

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1713:  
Lapatinib (Tyverb<sup>®</sup>) 250 mg film-coated tablets. July 2013.